Visão geral da empresa
A biotechnology company, Immutep Limited engages in the development of novel immunotherapies centered on Lymphocyte Activation Gene-3 for the treatment of cancer and autoimmune diseases within Australia. This enterprise operates within the broader Healthcare sector, specifically the Biotechnology industry, which typically involves high research and development expenditures to bring innovative biological products to market. The company's current market capitalization stands at $47.34M, while its trailing twelve-month revenue is recorded at $7.92M, with no specific employee count disclosed in available data. These valuation and revenue figures indicate that the company is a small-cap entity, suggesting it is in an early-to-mid stage of commercialization where revenue growth potential is significant but the absolute scale of operations remains limited compared to large-cap peers.
Saúde financeira
Immutep Limited reported a revenue of $7.92M over the trailing twelve months, yet it recorded a net income of $-83,916,456, highlighting a substantial gap between top-line generation and bottom-line profitability. This significant disparity reveals a cost structure heavily weighted toward research, development, and operational overheads that currently exceed all generated revenue, a common characteristic in pre-revenue or early-revenue biotechnology firms. The company's EBITDA stands at $-82,390,280, further confirming that operating expenses are consuming the entirety of the company's cash inflows. Free cash flow is negative at $-35,678,096, which indicates that the company is burning cash to fund its operations and pipeline development, thereby limiting its immediate financial flexibility without external capital raises. The gross margin is 0.0%, while the operating margin is -763.7% and the profit margin is 0.0%, reflecting a business model where costs of goods sold and operating expenses are disproportionately high relative to sales volume. The balance sheet shows a cash position of $99.13M against total debt of $1.21M, resulting in a debt-to-equity ratio of 1.22. Despite the high debt-to-equity figure, the company holds a massive cash reserve that significantly outweighs its liabilities, suggesting the balance sheet is not leveraged in a traditional sense of risk but rather funded to support long-term R&D. The current ratio is 2.97, indicating that the company possesses nearly three times the current assets required to cover its short-term liabilities, which points to strong short-term liquidity management. Return on Equity is -61.8% and Return on Assets is -32.1%, metrics that reveal that management effectiveness, in terms of generating profit from equity and assets, is currently negative due to the lack of profitability in the current business cycle.
Avaliação de valorização
The company exhibits a P/E Ratio (TTM) that is not applicable due to net losses, while the Forward P/E is listed as -1.46, a metric that implies future earnings are still expected to be negative or that the market is pricing in significant turnaround risks. The price-to-book ratio stands at 6.93, indicating that the market values the company at nearly seven times its book value, suggesting a premium placed on its intellectual property and potential future pipeline rather than current tangible assets. The price-to-sales ratio is 5.97, and the EV/EBITDA is -4.56, providing alternative valuation perspectives that highlight the company's high multiple relative to sales despite its lack of earnings, typical for high-growth biotech assets with substantial cash reserves. The stock has traded between a 52-week low of $0.32 and a 52-week high of $3.53, demonstrating significant price volatility within the year. Given the 52-week high of $3.53 and low of $0.32, the current price context within this specific range depends on the real-time market price which fluctuates, but the historical range defines the asset's maximum expansion and contraction observed in the recent year. The Beta is 2.32, which means the stock price is expected to be approximately 2.32 times more volatile than the broader market index, signaling high sensitivity to market sentiment and sector-specific news.
Growth & Income
Revenue growth year-over-year is recorded at 91.5%, whereas earnings growth is not applicable (N/A) due to the company's consistent net losses, implying that top-line expansion is outpacing the ability to generate profitability in the current fiscal cycle. As the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, meaning the company reinvests all available earnings and cash reserves back into research, development, and operational scaling rather than distributing income to shareholders. This lack of dividend payments is standard for biotechnology firms that prioritize capital allocation toward pipeline advancement to achieve future commercial milestones. Overall, the company presents a growth profile characterized by double-digit revenue expansion and significant cash reserves, but an income profile that offers no current yield and relies entirely on future potential earnings realization.